President implored Republicans to make a better case for how much prices are easing in America ahead of next year's mid-term ...

The share price of Danish pharmaceutical giant Novo Nordisk ( NVO +1.25%) hit a four-year low Monday, falling below $44 a ...

Things are changing rapidly in the pharmaceutical sector, but Eli Lilly remains in the pole position in weight loss drugs.

I also own Eli Lilly, too, so I can handle that pain. Lilly may have the greatest drug franchise of all time with this GLP-1 ...

Novo Nordisk ( ($NVO) ) has risen by 8.32%. Read on to learn why. Novo Nordisk’s stock has seen an impressive 8.32% rise over the past week, ...

The next-generation “GLP-1 plus” drugs will be tailored to the health needs of individual patients.

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment ...

Novo Nordisk A/S (NVO), though cheap at 13x forward earnings, is in my view a value trap, as growth is slowing and GLP-1 ...

Eli Lilly announced trial results for its weight-loss medication, orforglipron, in August. Orforglipron is a once-daily oral ...

Investors will want to see these key developments concerning Novo Nordisk's pipeline of new treatments. The company revealed ...

"Ozempic 2.0" has been floating around online, as a trending nickname for the next generation of weight loss drugs that are in the works.

When Marilou Paladin, 42, of Quezon City, began her weight-management journey, her biggest hurdle wasn't portion control. It ...